Pancreatic Cancer Research

ResearcherWashington University in St. LouisActive in the last 2 years

Patrick M. Grierson

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0624-6699; OpenAlex author ID A5065232573; NIH RePORTER profile ID 10600665. Sources: ClinicalTrials.gov.

Their work

Papers
11 (first author 1, last author 0)
Trials
2 (principal investigator on 2)
Grants
1
Labs led
0
Collaborators
36
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 3 papers · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper, 2 trials, 1 grant

Papers 11

  1. Adaptive Salvage Stereotactic Radiation for Locoregional Recurrence of Pancreatic Adenocarcinoma After Surgery. Co-author DOI 10.1016/j.prro.2026.03.015↗
  2. Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-24-1821↗
  3. Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer. Co-author DOI 10.1038/s41467-024-46811-w↗
  4. Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1093/oncolo/oyac237↗
  5. A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy. Co-author DOI 10.1158/1078-0432.ccr-23-1405↗
  6. IRAK4 Signaling Drives Resistance to Checkpoint Immunotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2022.02.035↗
  7. CC Chemokine Receptor 2-Targeting Copper Nanoparticles for Positron Emission Tomography-Guided Delivery of Gemcitabine for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1021/acsnano.0c08185↗
  8. The MK2/Hsp27 axis is a major survival mechanism for pancreatic ductal adenocarcinoma under genotoxic stress. Co-author DOI 10.1126/scitranslmed.abb5445↗
  9. Stroma-targeting strategies in pancreatic cancer: Past lessons, challenges and prospects. First author DOI 10.3748/wjg.v27.i18.2105↗
  10. Phase Ib/II study combining tosedostat with capecitabine in patients with advanced pancreatic adenocarcinoma. Co-author DOI 10.21037/jgo.2019.11.06↗
  11. Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models. Co-author DOI 10.1158/1535-7163.mct-17-1142↗

Trials 2

  1. ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma Principal investigator NCT06904378↗
  2. Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma Principal investigator NCT07126158↗

Grants 1

  1. Targeting Tumor Intrinsic and Extrinsic Survival Signaling to Overcome Resistance to Radiation Therapy in Pancreatic Cancer. R01CA303033↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. David G DeNardo · 4 shared papers, 1 shared grant, 2022–2026 · strength 1.73
  2. Kian‐Huat Lim · 11 shared papers, 2018–2026 · strength 1.68
  3. Hyun Kim · 1 shared grant, 2026 · strength 1.00
  4. Andrea Wang‐Gillam · 6 shared papers, 2018–2025 · strength 0.84
  5. Benjamin R. Tan · 4 shared papers, 2020–2025 · strength 0.61
  6. Katrina Sophia Pedersen · 4 shared papers, 2020–2025 · strength 0.61
  7. Paarth B. Dodhiawala · 4 shared papers, 2018–2024 · strength 0.49
  8. Daoxiang Zhang · 3 shared papers, 2018–2022 · strength 0.34
  9. Sapana Bansod · 2 shared papers, 2023–2024 · strength 0.31
  10. Vikas Somani · 2 shared papers, 2022–2024 · strength 0.29
  11. Lin Li · 2 shared papers, 2021–2022 · strength 0.26
  12. Carl DeSelm · 1 shared paper, 2026 · strength 0.25
  13. David S. Lakomy · 1 shared paper, 2026 · strength 0.25
  14. Dominic E. Sanford · 1 shared paper, 2026 · strength 0.25
  15. Richard Tsai · 1 shared paper, 2026 · strength 0.25
  16. Roheena Z. Panni · 1 shared paper, 2026 · strength 0.25
  17. Hyun Jee Kim · 1 shared paper, 2026 · strength 0.25
  18. Michael Richard Waters · 1 shared paper, 2026 · strength 0.25
  19. Faran Polani · 1 shared paper, 2021 · strength 0.22
  20. John M. Baer · 1 shared paper, 2025 · strength 0.19
  21. Channing J. Der · 1 shared paper, 2023 · strength 0.16
  22. William G. Hawkins · 1 shared paper, 2024 · strength 0.15
  23. Ashenafi Shiferaw Bulle · 1 shared paper, 2024 · strength 0.15
  24. Ramaswamy Govindan Md · 1 shared paper, 2024 · strength 0.15
  25. Li Ding · 1 shared paper, 2024 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.